From studying HLA in transplantation to cancer immunotherapy, our proteins can be used in a wide variety of applications suited for your needs.
HLA Applications
Navigate through our HLA related applications including detection, induction, elimination, and regulation of immune responses. Use our proteins to accelerate your research in the fields of transplantation, cancer malignancies, infectious diseases, or autoimmunity.
Choose from a range of HLA applications
HLA TRANSPLANT TECHNOLOGIES
Use our extensive library of sHLA proteins to develop new pre- and post-transplant diagnostic and therapeutic solutions to promote greater longevity and availability of organ grafts.
HLA IMMUNOPEPTIDOMICS
Use our sHLA tools to discover the world of T-cell epitopes that mediate disease control or improved survival and reach new horizons in the development of personalized vaccines and therapeutics.
HLA IMMUNOBIOLOGICS
Use our modified sHLA molecules to explore T cell reactivities for the world’s leading diseases and gain unique insight into the behavior of your vaccines or therapeutics.
HLA TRANSPLANT TECHNOLOGIES
In organ transplantation, the presence of antibodies to HLA, whether pre-existing or transplant-induced, continues to represent the major obstacle to successful organ transplantation and long-term graft survival. HLA Protein Technologies Inc. has developed a soluble Human Leukocyte Antigen (sHLA) technology to provide novel diagnostic and therapeutic applications in transplantation medicine.
HLA Protein Technologies Inc. utilizes these proprietary sHLA proteins for:
- Screening diagnostics for identifying offending Donor Specific Antibodies (DSA);
- Diagnostic tests for monitoring of offending DSA levels in chronic patients
- Research Assays to characterize DSA’s and their interaction with HLA
- Diagnostic tests for B cell-based HLA antibody detection and monitoring
- Diagnostic and therapeutic HLA antibody removal columns for removal of only specific DSA
HLA IMMUNOPEPTIDOMICS APPLICATIONS
HLA peptidomics is an emerging field that targets endogenously produced protein fragments. The rich repertoire of peptides presented by HLA Class I and Class II complexes, referred to as the HLA ligandome or immunopeptidome in tumor cells, reflects the health state of a cell. As such, the HLA-bound peptide’s ability to interact with T-cells is crucial and serves as the leading target for designing innovative therapeutics and vaccines against cancer, infectious diseases, and autoimmunity.
While the immuno-oncology world is rapidly evolving with numerous targeted therapies, the challenge facing drug developers remains the selection and validation of novel targets. HLA Protein Technologies Inc. specializes in epitope target discovery and validation for the world’s leading diseases, utilizing the proprietary sHLA peptide binding assay platform to screen, identify, and validate unique HLA-derived T cell peptide epitopes found on cancer targets or as part of the pathogen in infectious diseases. Numerous technologies and capabilities including proprietary assays and know-how are offered to a broad range of customers.
HLA IMMUNOBIOLOGICS
Our HLA Immunobiologics platform specializes in HLA peptide complex engineering and the development of HLA-based immunotherapeutic reagents. We generate and validate soluble HLA class I molecules loaded with custom peptides to create high-quality HLA:peptide complexes (HLApep), which serve as immunogens for the development of TCR-like antibodies (TCRm), engineered T cell receptors, and other HLA binding receptors. These reagents enable precise targeting of tumor-associated, viral, or self-antigens, supporting applications across cancer immunotherapy, infectious disease therapy, autoimmune modulation, and allergy management. By combining proprietary HLA peptide exchange technologies, rigorous binder validation, and cross-reactivity assessment, our platform provides the essential tools to design, optimize, and characterize next-generation T cell- and HLA-based therapeutics and diagnostics.
You might also be interested in…
Soluble HLA Class I Proteins
Mammalian produced, endogenously loaded, and naturally folded recombinant soluble HLA Class I proteins
Soluble HLA Class II Proteins
Mammalian produced, zipper stabilized, endogenously loaded, and naturally folded recombinant soluble HLA Class II proteins
Peptide Validation and Screening Services
Competition-based HLA peptide binding assays for the validation and screening of putative T cell epitopes
